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Background: Variants of the interferon-lambda3 (IFNL3) gene have been associated with both spontaneous and
treatment induced clearance of HCV infection. Attempts to link polymorphisms of the IFNL3 gene with variation in
the level of IFNL3 expression have been inconclusive. This is partially due to the difficulty to design assays
distinguishing IFNL3 from IFNL2.
Methods: In this study an allele specific real-time PCR (RT-PCR) assay was developed which allows the relative
quantification of the two IFNL3 transcripts in cells heterozygous for SNP IFNL3.rs4803217 in the 3'UTR of the IFNL3
gene. This SNP is in strong linkage disequilibrium (LD) with the predictive marker rs12979860.
Results: Raji cells showed two-fold increased levels of IFNL3.rs4803217 C-allele expression. In peripheral blood
mononuclear cells (PBMCs) of eight uninfected donors, two donors showed increased IFNL3.rs4803217 C-allele
expression.
Conclusion: This indicates that allele specific differences in IFNL3 expression vary between individuals and might
contribute to the variety of outcomes in HCV infected patients.
Keywords: Variation of allele specific expression, Quantitative RT-PCR, IFNL3 gene, Hepatitis C Virus (HCV) infection,
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Recently genetic polymorphisms in the interferon-lambda3
gene (IFNL3), also known as interleukin 28B (IL-28B) have
been shown to be highly associated with the outcome and
treatment response of Hepatitis C infection in ethnically
diverse cohorts [1-6]. Several single nucleotide poly-
morphisms (SNPs) are in linkage disequilibrium (LD),
which makes the identification of the functional poly-
morphism challenging. Attempts have been made to link
the effects of the polymorphism to a difference in the level
of expression of IFNL3 transcript in vitro and in vivo [4,7]
or differences in potency of the corresponding gene prod-
ucts [8], but no consistent difference could be detected.
The challenge with designing genotyping assays for
IFNL3 is the close homology with IFNL2 (IL28A), with
which it shares 96% homology on the DNA level [4,9].
Several IFNL3 specific TaqMan assays have been de-
signed which discriminate IFNL3 from IFNL2 [8,10], but* Correspondence: s.knapp@imperial.ac.uk
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unless otherwise stated.are not able to discriminate between the two alleles
within the gene. In order to study the allele specific ex-
pression of IFNL3, we developed a SYBRGreen based
RT-PCR assay which is able to quantify the two allele
specific transcripts of IFNL3 (whilst excluding a signal
from IFNL2) based around the two expressed alleles of
the rs4803217 SNP in the 3’UTR region of IFNL3. In the
Asian and Caucasian population SNP rs4803217 is in
close LD with rs12979860 (r2 = 0.98 [11,12]), which pre-
dicts outcome of HCV infection and treatment response.
The relative amount of allele specific transcript was mea-
sured after interferon stimulation of Huh7, Raji and Jurkat
cells, and in peripheral blood mononuclear cells (PBMCs)
of eight uninfected healthy donors, which were heterozy-
gous for IFNL3.rs4803217. The assay is a modification of
allele specific quantitative RT-PCR, which has been devel-
oped by Germer et al. [13] to accurately measure varying
allele frequencies between 5% and 95% for SNPs in pooled
DNA samples. We report that the presented IFNL3 spe-
cific assay is able to accurately measure variation of allele
specific expression between individuals.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Cell lines
The cell lines used in our experiments were Huh7, Raji
and Jurkat cell lines. The Huh7 cell line is derived from
hepatocellular carcinoma [14]. The Raji cell line is a sus-
pension cell line derived from B-lymphocytes [15]. The
Jurkat suspension cell line is derived from T-cells [16].
Huh7, Jurkat, Raji cells were cultivated under standard
conditions in DMEM medium containing 5% Pen/Strep
and 10% heat inactivated Foetal Calf Serum (FCS) and
incubated at 37°C under 5% CO2/air. Confluent Huh7
and stationary phase Raji and Jurkat cells were diluted to
2 × 105 cells/ml into 1 ml of medium in 12-well plates.
On the following day, when the number of cells reached
4 × 105 cells/ml, cells were stimulated by adding interferon
alpha (IFNα) (30–2000 Units/ml; Roferon, Roche) [17],
interferon beta (IFNβ) (50–1000 Units/ml; human inter-
feron β1a, Sigma)[18], interferon gamma (IFNγ) (50–
500 ng/ul; R&D systems)[19], interferon lambda 3 (IFNλ3)
(IL-28B 500 ng/ml; R&D systems) [20], toll like receptor 7
(TLR7) agonist RWJ21757 (10 μmol; R&D systems) [21]
or tumour necrosis factor alpha (TNFα) (40 ng/μl; R&D
systems) [22].
Huh7, Raji and Jurkat cells were tested for the expres-
sion of interleukin 10 receptor beta (IL10RB), interferon
alpha receptor (IFNαR), IFNL2/3 IL28, 2'-5'-oligoadenylateFigure 1 Schematic location of the rs4803217 SNP in relationship to o
linkage disequilibrium in Caucasians (r2≥ 0.92) [12]. The linkage disequilibri
diagram and displayed as r2 (10;32), with a lower linkage disequilibrium rep
sequence around rs4803217 is shown for IFNL3 and IFNL2 with primers des
contains a mismatch to IFNL2 at position 11 (from the 5’end) for IFNL3 spec
specific primer ends with A at the 3’ end, and the C allele specific primer e
IFNL3 specific mismatch to IFNL2 at the 3rd base from the 3’ end. Mismatch
specific base within each primer is underlined.synthetase (OAS1) and myxovirus (influenza virus) resist-
ance 1 (Mx1) (with GAPDH as a housekeeping gene)
using primers published by Diegelmann et al. [23].
Peripheral Blood Mononuclear cells (PBMCs)
Peripheral blood mononuclear cells (PBMCs) from eight
consented uninfected donors heterozygous for the IFNL3.
rs4803217 polymorphism were isolated using Hypaque-
Ficoll (Amersham Biosciences) density centrifugation.
1–5 × 106 cells in 1 ml of medium were stimulated
with 800 Units /mls IFNα for 6 hours.
Genotyping of cell lines and healthy donors
SYBRGreen based RT-PCR was used to characterize the
genomic DNA of cell lines and uninfected donors for
the IFNL3 polymorphisms rs12979860, rs8103142 and
rs4803217. The schematic location of these SNPs and
their pairwise linkage disequilibrium is shown in Figure 1A.
Primers were designed by the author to be specific for
IFNL3 and ordered from Invitrogen. Primer sequences
are listed in Table 1. The position of the three primers
for the rs4803217 RT-PCR assay within the sequence of
IFNL2/3 is illustrated in Figure 1B.
Each DNA sample was interrogated twice, once with
the primers specific for allele 1 (A) in combination with
the common primer, then with the primer specific forther SNPs in and near the IFNL2/3 gene. All four variants are in high
um between the four markers is represented in the table below the
orted between rs12979860 and rs8099917 [11]. (A) The nucleotide
igned to be specific for IFNL3 (B). The IFNL3 specific forward primer
ificity. To distinguish A and C allele of the rs4803217 SNP, the A
nds with C at the 3’ end. The reverse common primer contains one
es between IFNL3 and IFNL2 are highlighted by asterix*, and the IFNL3
Table 1 Primer sequences for IFNL3 genotyping and expression studies
SNP Location Allele specific primer (5’- > 3’) Common primer (5’- > 3’)
rs12979860 3 kb upstream gcattcaaccctggttcA gcttatcgcatacggctaggc
gcattcaaccctggttcG
rs8103142 exon 2 (K70R) cttctgctgaaggactgcaA tgagcagggctgggagg
cttctgctgaaggactgcaG
rs4803217 3’UTR cgactgggtgacaataaattaagA cctgtgtgtctgacccttcc
cgactgggtgacaataaattaagC
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mer. The genotyping method using the primer com-
bination for IFNL3.rs12979860 has been described
earlier [24].
Reactions were performed in 96 well plates with
10 ng/μl genomic DNA and 0.5 μM of each primer (one
allele specific and one common primer per reaction) in
the presence of a SYBRGreen containing reagent mix
(QuantiTect, Qiagen) using a StepOnePlus instrument
(Invitrogen). The cycling conditions were initial denatur-
ation of 10 min 95°C, 40 cycles of 15 seconds 95°C and
60 seconds 60°C, followed by a melt curve.
Genomic DNA for the validation of the method was
used as 10 ng/ul after quantification with a NanoDrop
spectrophotometer (Thermo Fisher).
cDNA synthesis
RNA was extracted from cells following the RNeasy
protocol (Qiagen) and from frozen PBMCs of uninfected
donors using Trizol reagent (Invitrogen) in a standard
protocol including DNAse treatment. cDNA was synthe-
sized using the Retroscript kit (Ambion) according to
manufacturer’s instructions, but using oligo dTs and ran-
dom decamers (2.5 μM each) in combination to optimize
the efficiency of the cDNA synthesis. 1ug of RNA was
transcribed into cDNA.
Relative quantification of gene expression by real time PCR
The same assay, including conditions and primers, which
was used for genotyping was also used for relative quanti-
fication of allele specific gene expression. But in contrast
to the genotyping assay, samples were run in triplicates
for each allele specific reaction. 1 μl of a 20 μl of cDNA
(cDNA from 50 ng of RNA) volume was put in each reac-
tion. In order to use the assay for quantification of allele
specific expression, the bias induced by the difference in
amplification efficiency between the two allele specific re-
actions was corrected for by the use of a heterozygous
genomic control in each experiment.
In order to validate the genotyping assay for its use in
detecting potential 1.5 to 2 fold differences between the
expression of the two alleles of IFNL3.rs4803217, different
ratios of the two alleles from two DNAs homozygous for
the respective alleles were combined and their respectivedCt (difference between Ct value of allele 1 and 2) mea-
sured using the IFNL3.rs4803217 genotyping assay. Assum-
ing both allele specific primers have the same amplification
efficiency of the assay, the reaction specific for allele1
should get amplified after the same number of amplifica-
tion cycles than allele 2, and dCt should be zero for a
heterozygous sample carrying the same amount of allele
1 and 2. The same results (with exception of DNA meas-
urement and pipetting errors) should be approximated if
allele 1 and allele 2 are combined in a 1:1 ratio from the
two homozygous DNA samples. If the alleles are present
in a ratio 1:2, with allele 2 having twice the frequency of
allele 1), then allele 2 should get amplified one cycle earlier
(as each cycle leads to duplication of the number of ampli-
fied copies) and the dCt should be 1. Therefore the rela-
tionship between ratio and dCt is represented by equation
[1]: Ratio = 1:2dCt. Allele 1 (A) and 2 (C) were combined in
ratios 4:1, 3.1, 2.5:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:4.
The results were corrected with the dCT of the het-
erozygote genomic DNA control (HH23), which com-
pensates for the difference in amplification efficiency of
the two alleles. The relationship between known ratios
of the two alleles and measured dCt values is shown in
Figure 2.
The inability of the assay to discriminate against genomic
DNA present in the sample is off-set by the advantage of
internal validation using three sequenced genotyping con-
trols. As the genomic DNAs of the cells tested for variation
of allele specific PCR are heterozygous for the SNP which
the assay is detecting, they cannot contribute to variation
in allele specific expression. Therefore any observed vari-
ation (after correction for the bias introduced through un-
equal amplification efficiency of the two allele specific
reactions which is calculated by including a genomic het-
erozygous control in each assay) can be attributed to a
variation in allele specific expression. RNA (without re-
verse transcription) controls were also included in each
assay in order to detect amplification resulting from gen-
omic DNA in the cDNA.
Statistical analysis
Data were analysed using Graph Pad Prism. The Mann–
Whitney U test was applied to compare the means of
the difference in allele expression between heterozygote
Figure 2 Relationship between dCt and varying ratios of allele 1 (allele A) and 2 (allele C) measured by the IFNL3.rs4803217 assay. The
assay shows the differences in the Ct value (dCT) of the rs4803217 assay for different ratios of C: A allele. The differences (dCt) in the Ct value for
11 different ratios between A and C allele (4:1, 3:1, 2.5:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:4) is plotted after correction with the difference
observed in the heterozygous genomic control (HH23) , where the ratio A:C is exactly 1:1. Sensitivity of IFNL3.rs4803217 assay to detect 1.5-4 fold
changes in allele specific expression. Data points are the mean of triplicate reactions and error bars indicate +/− SEM.
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four experiments in Raji cells, using three independently
synthesized batches of cDNA from two independent
stimulation events. Data obtained from the eight unin-
fected donors were analyzed in the same way. Two
tailed p–values are calculated. Data are expressed as
mean +/− SEM.
Results
Genotyping of cell lines and healthy donors
The rs4803217 RT-PCR assay is specific for IFNL3
(Figure 1B), as it distinguishes three genotypes (Figure 3).
It excludes the amplification of IFNL2, which has the A al-
lele “fixed” in the position of the rs4803217 SNP ( 3’ end
of the specific primer) . Cross reactivity with IFNL2 wouldFigure 3 The IFNL3.rs4803217 assay distinguishes three IFNL3
specific genotypes. The Ct value is plotted for te amplification of
the A and C allele specific primers respectively in each of the three
genotypes.. In a sample with AA homozygocity (HH3), the A allele is
getting amplified much earlier (dCt≥ 6) in comparison to the C
allele; in a sample with CC homozygocity (HH16), the C allele is
getting amplified much earlier than allele A (dCT = −6). In the case
of AC heterozygocity (HH11), both alleles are amplified after almost
the same number of cycles (dCt = 0.06-1).not allow the detection of CC homozygocity if this primer
also recognized the A allele of IFNL2. The differences be-
tween the crossing points (dCt values) for the two alleles
of IFNL3.rs4803217 is robustly greater than dCT = 6 for
homozygotes AA or CC in the absence of the other allele,
whereas in heterozygotes the average dCt between the two
allele specific reactions varies between 0.06 and 1 (assay
variability) which is the result of the difference in amplifi-
cation efficiency for the two alleles. To further confirm
the IFNL3 and allele specificity of the rs4803217 assay, we
sequenced amplicons which suggested AA and CC homo-
zygocity respectively from samples which had been used
as controls in each assay. We confirmed that the products
were IFNL3 and allele specific (Additional file 1: Figure
S1: Sequence of amplification products).
Huh7, Jurkat and Raji cells are heterozygous for the
IFNL3.rs12979860, IFNL3.rs8103142, and IFNL3.rs4803217
polymorphisms (Figure 1A), thus making it an ideal sys-
tem for the relative comparison of the expression levels of
the two alleles. RNA controls revealed that only negligible
amounts of genomic DNA were present in the cDNA
samples used. Eight uninfected donors heterozygous for
rs4803217 were also heterozygous for rs12979860 and
rs8103142, which confirms the strong linkage disequilib-
rium between the three markers.
Relative quantification of gene expression by real time
PCR
Huh7, Raji and Jurkat cells showed constitutive expression
of IL10RB, IFNαR and inducible expression of IFNL2/3,
OAS1 and Mx1 (with GAPDH as a reference) after stimu-
lation with 800 iU/ml IFNα, indicating that the receptors
for the recognition of the IFN stimulation are intact and
IFNL2/3 is induced. Additional file 2: Figure S2 (induction
of OAS etc after IFNa stimulation) shows the induction of
OAS and IFNL2/3 in Huh7 cells after 3, 6, 8, 12 and
24 hours of stimulation with 800 iU IFNα.
Figure 4 Relative level of IFNL3.rs4803217 C-allele specific
transcript detected in Raji cells heterozygous for IFNL3.
rs4803217 after stimulation with 800 iU IFNa, compared to a
genomic heterozygote control. The ratio of C:A allele is expressed
as 2^dCt after correction with the differences observed in the
genomic heterozygote control. The results of 4 independent
experiments are shown. The p-value 0.029 was calculated using the
Mann–Whitney U test.
Figure 5 Relative levels of IFNL3.rs4803217 C-allele specific
transcript detected in frozen PBMCs from eight uninfected
donors heterozygous for IFNL3.rs4803217 after stimulation with
800 iU IFNα, compared to a genomic heterozygote control. The
ratio of C:A allele is expressed as 2^dCt value after correction with
the differences observed in the genomic heterozygous control.
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duction of IFNL3 expression was optimal using 800 iU/mls
IFNα and 6 hour incubation (see also Additional file 2:
Figure S2 (gene induction)). Therefore IFNL3 expres-
sion for this manuscript was measured following this
protocol. IFNβ showed the best induction after 6 hours
of 500 iU/mls IFNβ, and IFNλ at 500 ng/ml. Both were
less efficient in the induction of IFNL3 expression and
did not lead to reproducible comparisons of allele specific
IFNL3 expression. Toll like receptor 7 (TLR7) agonist
RWJ21757 and tumor necrosis factor alpha (TNFα) were
unable to induce detectable levels of IFNL3 expression in
Huh7 cells (data not shown) and were not tested in Raji
or Jurkat cells.
As the validation experiment shows, the IFNL3.rs4803217
allele specific PCR assay is able to measure the relationship
between dCt and 1.5-2 fold changes in the ratio of the two
specific alleles (Figure 2). We therefore concluded that the
assay for IFNL3.rs4803217 is suitable to measure a differ-
ence in the expression of the two alleles in cells heterozy-
gous for the IFNL3.rs4803217 SNP.
Using the IFNL3.rs4803217 genotyping based quanti-
tative RT-PCR assay, we detected a two-fold increased
expression of IFNL3.rs4803217 C specific transcript in
Raji cells in four independent experiments (fold-change
2.09 (95% CI = 0.94-1.07) versus 1.01 (95% CI = 1.50-
2.70), p = 0.029). The combined result of the four exper-
iments is represented in Figure 4. In order to validate
the results in primary cells we looked at allele specific
IFNL3 expression in eight healthy donors heterozygous
for the IFNL3.rs4803217 polymorphism. The relative
expression levels of the two alleles showed variation be-
tween individuals, with ratios of C to A allele ranging
between 1.4 and 0.7. Two of the eight donors showed an
increased IFNL3.rs4803217 C allele expression. The re-
sults were reproducible for each individual. The differ-
ences in the ratios did not reach statistical significance
(Figure 5). Due to the relatively low expression of the
IFNL3 gene in the B cells of uninfected subjects [23], we
were unable to measure allele specific IFNL3.rs4803217
expression in their B cells (data not shown)
Discussion
In order to develop an assay that is able to measure the
expressed products of IFNL3 in an allele specific man-
ner, the 3’UTR SNP rs4803217 was chosen, as it is in
strong linkage disequilibrium with rs12979860, a pre-
dictive marker for the clinical outcome of HCV infec-
tion and treatment response. The assay clearly excludes
the amplification of IFNL2 specific sequence as it shows
the distinction of three genotypes including AA homo-
zygocity, which would not be possible if the C allele of
IFNL2 was present. In addition our assay is also able to
discriminate between the two variants of the IFNL3.
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increased expression of the IFNL3.rs4803217 C allele in
Raji cells at 2 fold level. No difference in the relative
level of allele specific expression was observed for Huh7
and Jurkat cells. Raji cells are derived from a B-cell line,
where high levels of IFN-λR have been detected, sug-
gesting that B-cells are actively involved in IFNL3 sig-
nalling [25]. Raj cells are reported to produce higher
levels of IFNL3 compared to Huh7 or Jurkat cell lines
[10], which supports the finding that allele specific dif-
ferences of expression can be context and tissue specific
[26]. Unfortunately expression of IFNL3 in the B-cell
population of the healthy donors resulted in undetect-
able levels of IFNL3 due to the low expression of IFNL3
and smaller number of cells available (data not shown).
In order to validate our assay in primary cells, we se-
lected eight uninfected donors heterozygous for rs4803217
and rs12979860. The C allele was up-regulated in two of
the eight donors. We detected marked variation in the
relative ratio between the C and A allele, ranging from 1.4
to 0.7. Although this variation is not as high as the 2 fold
increase as the expression of the C allele in Raji cells, and
not as clear cut as a 1.5 ratio from the standard curve in
Figure 2, the ratio was clearly reproducible for each donor.
The C allele of IFNL3.rs4803217 is in LD with the C
allele of IFNL3.rs12979860, which is associated with a
high frequency of clearance and treatment response.
Our results indicate that in certain cells or individuals
the rs12979860 CC and also CT genotype are possibly
producing more IFNL3 transcript than the TT geno-
type, an observation which had been reported earlier
using whole blood samples [4], but was not confirmed
in liver tissue [8]. In contrast to Suppiah’s approach [4]
where allele specific variation is measured by comparing
IFNL2/3 expression in individuals homozygous for the
two alleles of rs12979860, our assay is specific for IFNL3
and is carried out in heterozygotes, so that a comparison
of expression between the two alleles within the same cell
is less likely to be subject to confounding variables.
Our results obtained in eight uninfected healthy do-
nors heterozygous for the IFNL3 SNP rs4803217 (and
consequently rs12979860) suggests that variation exists
between individuals with regards to allele specific ex-
pression. As we only study the differences observed in
the allele specific expression of heterozygotes, we cannot
exclude that homozygosity of each of the alleles could re-
sult in a greater effect of the genotype variation.
Variation in allelic gene expression affects 20-50% of
human genes and may account for variation in the trans-
mission of diseases and disease outcomes [27-29].
It has been reported that differences in allele specific
expression are inherited, but that only 3-30% of individuals
exhibit the allele specific expression [27]. It was shown that
allelic variation in the adenomatous polyposis coli (APC)gene expression plays a critical role in colon cancer [30].
Variation in allelic expression was also measured for the
rs2834167 SNP in IL10RB in Epstein Bar virus (EBV)
transformed B-cell line heterozygous for this SNP and
might be the underlying functional cause for the association
of this SNP with the outcome of HBV infection [31].
In the literature conflicting results are reported with
regards to IFNL3 expression in PBMCs versus liver,
and differences seem to exist between healthy and
chronic donors. In our technical manuscript we use
PBMCs of healthy donors to develop the assay as a tool
which is able to measure IFNL3 and allele specific ex-
pression of IFNL3 transcripts in patient cohorts. A few
publications have shown a potential role of blood and
immune cells in the recruitment process to the liver
during inflammation. Although the expression status
of cells might differ between healthy donors and dur-
ing the process of inflammation, PBMCs are a valid
starting point for measuring allele specific expression
of IFNL3 [32].
As we did not find consistent up-regulation of the C
allele in eight donors heterozygous for the C allele of
IFNL3.rs4803217 and rs12979860, we investigated the
possibility that the observed variation in expression of
the rs4803217 C transcript is influenced by other
SNPs in the IFNL3 region. It has been reported that a
new variant upstream of the IFNL3 gene, which is in
high linkage disequilibrium with rs12979860, and
leads to a frameshift mutation creating a new inter-
feron gene IFNL4, might explain the association with
the clinical outcomes of HCV infection [33]. It has
been noted that the expression of the IFNL3 gene is
dependent on the genotype of the novel ss469415590
SNP [34]. Genotyping all donors in our study for
ss469415590 revealed that they were all heterozygous
for ss469415590, thus excluding the possibility of an
influence of this variant.
In the three cell lines and eight donors heterozygous
for IFNL3.rs4803217 we find 100% linkage with the
IFNL3.rs12979860 marker. High LD between both
markers is characteristic for Asian and Caucasian popula-
tions [12] (HapMap database r2 = 0.9 and 0.7-0.8 respect-
ively), but reported to be at r2 = 0.4 for Sub-Saharan
samples. More recently it was shown that the IFNL3.
rs4803217 variation seems to affect the stability of the
transcript, which could be another way by which the
IFNL3 polymorphism exerts its function [35]. Our find-
ing of varying C:A allele expression in certain cells and
individuals could be a result of differential stability of the
transcript in different individuals. Further studies need to
be undertaken to explore the function of the rs4803217
polymorphism in the outcome of HCV infection and
treatment response, using an IFNL3 and allele specific
assay for rs4803217.
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In conclusion, we show that the allele specific assay for
IFNL3 which we developed is a useful tool to determine
the IFNL3.rs4803217 genotype and at the same time ac-
curately and directly compare the expression of two al-
leles of the IFNL3 gene within heterozygous cells. As the
rs4803217 SNP has been reported to have an effect on
the stability of the transcript [35] the developed assay
could be used for the measurement of allele specific
IFNL3 expression in patient groups with different HCV
outcomes and treatment response, to determine the clin-
ical relevance of the observed variation.
Additional files
Additional file 1: Figure S1. Sequences of amplification products of
IFNL3 allele specific rs4803217 assay. A: The products are IFNL3 specific at
position 11 from the 5’end of the forward primer (starting from GCT; A is
not part of the primer sequence), where IFNL3 is characterized by a T(A)
allele, whereas IFNL2 has a C(G) allele. The T(A) specific primer amplified
the TT(AA) homozygote, whereas the C(G) specific primers amplified the
GG (CC) homozygote. 5’ and 3’ describe the direction of the primer
extension during the amplification.
Additional file 2: Figure S2. Induction of OAS and IFNL2/3 by 800iU
IFNa after 3, 6, 8, 12 and 24 hours.
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